We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bayer and Matsushita in Diagnostic Alliance

By HospiMedica staff writers
Posted on 01 Jun 2001
A long-term strategic business relationship to jointly develop, manufacture, and market diagnostic products has been announced by Bayer Corp. More...
(Tarrytown, NY, USA) and Matsushita Electric Industrial Co. (Osaka, Japan).

Under the agreement, Bayer Corporation, through its Business Group Diagnostics, will acquire rights for the sale and marketing of newly developed products and services for a broad range of applications for the diagnostics market, while Matsushita will be primarily responsible for the development and manufacture of new products and services. Combining Bayer's knowledge of the diagnostics customer and marketplace with the technologic expertise of Matsushita will enable both companies to develop products that meet the needs of the worldwide in vitro diagnostics market, estimated to reach US$25 billion by 2005.

"The relationship will leverage our combined strengths to develop innovative diagnostics solutions that meet the changing needs of the health-care market,” said Rolf Classen, president of Bayer Diagnostics. "We have already begun work on products for blood glucose monitoring through our Self Testing segment in Elkhart, Indiana, and the future opportunities are limitless.”





Related Links:
Bayer
Matsushita

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.